Optimizing Decision-Making in CLL in an Era of Novel Agents

Download All
A comprehensive educational program featuring expert insight commentaries, an Interactive Treatment Decision Support tool, and a series of microeducation modules to fortify your practice in managing patients with CLL.
Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc
Matthew S. Davids, MD, MMSc

Microlearning Interactive Virtual Presentations

In this installment of CCO’s concise patient case series, Matthew S. Davids, MD, MMSc, discusses first-line treatment considerations for a patient with CLL with a del(17p) alteration.

Jeff P. Sharman, MD
Program Director
Matthew S. Davids, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2020 Expired: No longer available for credit

In this installment of CCO’s concise patient case series, Jeff P. Sharman, MD, discusses first-line treatment considerations for a fit patient with CLL and no high-risk features.

Jeff P. Sharman, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2020 Expired: No longer available for credit

In this installment of CCO’s concise patient case series, Jeremy S. Abramson, MD, MMSc, discusses first-line treatment considerations for an older patient with CLL.

Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 12, 2020 Expired: No longer available for credit

In this installment of CCO’s concise patient case series, Matthew S. Davids, MD, MMSc, discusses second-line treatment considerations for a patient with CLL who received previous chemoimmunotherapy.

Jeff P. Sharman, MD
Program Director
Matthew S. Davids, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2020 Expired: No longer available for credit

In this installment of CCO’s concise patient case series, Jeff P. Sharman, MD, discusses treatment considerations for a patient with CLL who initially progressed on chemoimmunotherapy and was intolerant to subsequent ibrutinib.

Jeff P. Sharman, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 1, 2020 Expired: No longer available for credit

In this installment of CCO’s concise patient case series, Jeremy S. Abramson, MD, MMSc, discusses treatment considerations for a patient with CLL requiring new treatment following BTK inhibitor– and venetoclax-based therapy.

Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 14, 2020 Expired: No longer available for credit
Provided by University of South Florida (USF) Health in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
CLL Society Logo
Educational grant provided by:
AbbVie Inc.
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings